News Snapshot:
News APS gets FDA IND approval for APS03118 to treat different cancer types APS03118 is a new drug that targets patients with various advanced cancer types, caused by rearranged during transfection (RET) gene alterations Applied Pharmaceutical Science (APS) has received the US Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application for APS03118. APS03118 is a new drug that targets patients with various advanced cancer types, caused by rearranged during transfection (RET) gene alterations. The cancer types include non-small cell lung cancer, thyroid cancer, pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer and other advanced solid...
